Select Language:
Jieya Biologic Technology, a prominent Chinese supplier of paper products, announced plans to create a subsidiary in Egypt focused on manufacturing, with an investment of approximately CNY467 million (USD68.4 million). The new facility will be situated within the China-Egypt Teda Suez Economic and Trade Cooperation Zone and is projected to produce 8.1 billion disposable sanitary products annually. The construction phase is expected to take around two years.
In December, Jieya formalized a land use agreement with the Teda Suez zone to acquire a 160,000-square-meter plot for the factory. This strategic move aligns with the company’s long-term growth plans, aiming to enhance its overseas manufacturing capabilities, better serve international customers, strengthen profitability and risk mitigation, and boost the global competitiveness of its products.
Last year, Jieya experienced a 41% increase in revenue, reaching CNY770 million, with net profit quadrupling to CNY77.3 million (USD11.3 million). This growth was largely driven by a doubling of overseas sales to CNY520 million, while domestic sales declined by 12%, falling to CNY250 million, according to its 2025 financial report.
Established in 1999, Jieya specializes in the research, development, manufacturing, and marketing of wet tissues. Its shares are traded on the Shenzhen Stock Exchange under the ticker SHE: 301108, and recently, they increased by 0.6%, trading at CNY28.11 (USD4.11) per share.
ChatGPT
Perplexity
Gemini AI
Grok AI
